Purchase this article with an account.
Rim Bouraoui, II, Najoua Ben Youssef, Nibrass Chaker, Ahmed Chebil, Moslem slim, Salma Touati, Fatma Mghaieth, Leila El Matri; Functionnal Benefit After Intravitreal Bevacizumab For Large Subretinal Hemorrhage Secondary to Causes Other Than Age Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4872.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate functional and anatomic effects of intravitreal bevacizumab in patients with large subretinal hemorrhage secondary to causes other than age related macular degeneration.
Three eyes of three patients with recent large subretinal hemorrhage involving the center of the macula secondary respectively to a traumatic choroidal rupture, to a retinal macroaneurysm and to a complication of scleral buckling. Duration of the hemorrhage was between 15 and 30 days, All patients were treated with a single intravitreal injection of 1.25 mg bevacizumab(0.05 ml). Best corrected visual acuity (BCVA), size of subretinal hemorrhage measured with fluorescein angiography, retinal thickness in optical coherence tomography (OCT), mean time of resorption of hemorrhage and ocular complications were evaluated.
At baseline mean size of hemorrhage varied from 5 to14 papillary diameter. BCVA was limited to light perception in 2 cases and to 20/200 in one case. Retinal thickness varied between 421 and 504µm. One month after injection, subretinal hemorrhage was transformed into fibrine with important decrease in size. BCVA improved varying from 20/200 to 20/40. Retinal thickness reduced from 228 and 318µm. Complete resorption of fibrine was observed in all cases after a mean duration of 3.83 months, final BCVA varied from 20/64 to 20/25. No ocular complication inherent to the injection and no retinal complication was observed after a mean follow up of 9.33 months.
Intravitreal bevacizumab seems to be a promising therapeutic option with fuctionnal benefit in eyes with large submacular hemorrhage secondary to causes other than age related macular degeneration. However further studies with controlled trials are necessary to assess this efficacy.
This PDF is available to Subscribers Only